Nebenwirkungen · Hycamtin
HYCAMTIN 1 mg powder for concentrate for solution for infusion HYCAMTIN 4 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-086069 · Präparat HOS-083256
Thrombocytopenia Severe (platelets <25 x 109/l) in 25% of patients (8% of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25% of patients (15% of courses). Median time to onset of severe thrombocytopenia was day 15 and the median duration was five days. Platelet transfusions were given in 4% of courses. Reports of significant sequelae associated with thrombocytopenia, including fatalities due to tumour bleeds, have been infrequent.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-20T15:26:00Z · SHA-256 b5faba0cb8dc430e883615daec0cf15a62742b0008cf3a57c33ebf39c2a0a4b9 · Passage c95c2a6770637c85b9ec994dc44e28c7bdfd9690041a5c0ead808781ae7d2c92 · Zeichen 4469–4920 im Abschnitt